Loading...
•
Sep 30, 2023
Edwards Lifesciences Q3 2023 Earnings Report
Edwards Lifesciences reported strong Q3 2023 results, driven by double-digit sales growth and multiple new therapy approvals.
Key Takeaways
Edwards Lifesciences reported a 12% increase in sales to $1.48 billion in Q3 2023. The company's TAVR sales grew by 11%, and it received several regulatory approvals for its innovative therapies. The company reiterated its full-year 2023 financial guidance of 10 to 13 percent constant currency sales growth.
Q3 sales grew 12 percent to $1.48 billion; constant currency sales grew 11 percent.
Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent.
Q3 EPS of $0.63; adjusted EPS of $0.59.
Reiterated full year 2023 financial guidance of 10 to 13 percent constant currency sales growth
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Edwards' full-year sales guidance remains unchanged for both the total company and each product group. The company continues to expect full-year total company and TAVR sales growth to be in the 10 to 13 percent range on a constant currency basis. Additionally, the company continues to expect full year 2023 adjusted earnings per share of $2.50 to $2.60. For the fourth quarter of 2023, the company projects total sales to be between $1.45 and $1.53 billion and diluted earnings per share of $0.60 and $0.66.
Positive Outlook
- Full-year total company sales growth to be in the 10 to 13 percent range on a constant currency basis.
- TAVR sales growth to be in the 10 to 13 percent range on a constant currency basis.
- Full year 2023 adjusted earnings per share of $2.50 to $2.60.
- Fourth quarter of 2023, the company projects total sales to be between $1.45 and $1.53 billion
- Fourth quarter of 2023, diluted earnings per share of $0.60 and $0.66.
Revenue & Expenses
Visualization of income flow from segment revenue to net income